TARGET-D 202
TARGET-D 202 Evaluating VS-7375 in KRAS G12D-Mutated Non-Small Cell Lung Cancer
VS-7375 is an investigational oral KRAS G12D (ON/OFF) inhibitor that is being studied in a Phase 2, open-label study known as TARGET-D 202. VS-7375 is being evaluated as a once daily, oral monotherapy in patients with previously treated, advanced KRAS G12D-mutated non-small cell lung cancer. The study is registered at ClinicalTrials.gov (NCT07659782).
Summary
Clinical Trial Overview
This study is evaluating the safety and efficacy of VS-7375 in people with previously treated, advanced non-small cell lung cancer (NSCLC) who have a KRAS G12D gene mutation. VS-7375 targets this mutation to help block signals that drive tumor growth. All participants will take VS-7375 as a monotherapy, and participants who have asymptomatic untreated brain metastasis assigned to a separate study group (Cohort C).
Eligibility and Inclusion Criteria
Each clinical trial has specific eligibility criteria, which may include factors such as age, sex, disease type or stage, prior treatments, and other medical conditions. Key criteria include:
Inclusion Criteria
- Are 18 years of age or older
- Have been diagnosed with unresectable locally advanced or metastatic NSCLC with a KRAS G12D mutation
- Have at least one tumor that can be measured on a scan
- Have received prior treatment for advanced non-small cell lung cancer
Exclusion Criteria
- Recent major surgery
- Received certain types of chemotherapy, anti-cancer therapy or radiotherapy
- Treatment with more than one prior investigational therapy
This is a summary of the main eligibility criteria. Eligibility is determined by the study doctor based on the trial’s requirements and an individual’s medical history and health status.
Clinical Trial Sites
TARGET-D 202 is actively recruiting and the most up-to-date trial sites can be found on the listing on clinicaltrials.gov. For more information, visit the listing or contact us at 781-292-4204 or VS-7375-202TrialSupport@verastem.com.
Participants are required to visit the study site at least once during the 28-day screening period. Following screening, site visits are dependent on assigned treatment arm and all cycles are 28 days:
- First 28-day treatment cycle: three site visits
- Remaining 28-day treatment cycles: one site visit
Financial assistance and/or travel reimbursement are available for participants enrolled in the study.